COMP <GO>
XNCR vs MRVI // ALTMAN Z-SCORE & DEBT/EQUITY
Xencor Inc. (NASDAQ) VS. Maravai LifeSciences Holdings Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: XNCR 5
— MRVI 2
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: XNCR
LAST: $29.21 (-2.60%) • MKT CAP: $2.17B
balance-sheet
4.32
LAST: $8.46 (-0.47%) • MKT CAP: $2.20B
balance-sheet
3.04
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XNCR VS. MRVI)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XNCR | MRVI | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 18.30% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -21.30% | -35.00% | +13.70 | XNCR | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.37% | -3.22% | -3.15 | MRVI | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -60.00% | 0.00 | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 13.70% | -28.30% | +42.00 | XNCR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 4.32 | 3.04 | +1.28 | XNCR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 3/9 | +1.00 | XNCR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 68.0 | 53.6 | +14.41 | XNCR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.17B | $2.20B | -$25.0M | MRVI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XNCR REV | MRVI REV | XNCR GROSS % | MRVI GROSS % | XNCR FCF | MRVI FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $125.6M | $185.7M | — | 18.3% | -$138.3M | -$70.7M |
| FY 2024 | $110.5M | $259.2M | — | 41.8% | -$208.3M | -$22.2M |
| FY 2023 | $174.6M | $288.9M | — | — | -$77.9M | $126.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XNCR // BETA —
MRVI // BETA —